Says it receives far more submissions than the space to publish British medical journal The Lancet has refused to publish India's rebuttal in connection with an article in which a drug-resistant superbug was named after New Delhi. The National Centre for Disease Control (NCDC), in the rebuttal, disagreed with the naming of the bacteria as New Delhi Metallo Beta-lactamase-1. However, Lancet Editor Richard Horton, while on a visit to India later, apologised...

International health journal Lancet has accused the Government of India of “suppressing truth” about the presence of a drug-resistant bacteria in the public water system here by “threatening” and “abusing” its own scientists. It also dubbed as “unfortunate” the government's denial of presence of such bacteria. Mark Toleman, one of the co-authors of the study that claimed to have detected the bacteria in the capital's waters, said it was named ‘New Delhi-beta-lactamase'...

“National organisations of health research should come together to provide effective stewardship” Proportion of published papers increased from 0·4 % in 1988 to 1·8 % in 2008 Only 1/4 public health research reports rated as being of adequate quality Expressing concern over the scarcity of research on the routine health-information system in both reports and published papers, which is crucial to track the response of the health system to the health needs of...

Tuberculosis continues to be a major health problem in India. But the unveiling of a new test to diagnose TB and drug resistance on World Tuberculosis Day (March 24) brings some hope into a bleak scenario. Last Thursday, on World Tuberculosis Day, for the first time since the 1880s there was probably some justifiable cause for jubilation. After centuries of grappling with sputum smear microscopy, developed way back in the 1880s,...

India’s drug regulator has refused to disclose key information about a controversial government study that provided Indian girls a vaccine designed to protect them from cervical cancer, amplifying suspicions about the study’s objectives. The Drug Controller General of India (DCGI) has refused to release for public scrutiny the study’s protocols, which are expected to contain information about its purpose and methodology, a set of health activists said yesterday. The Union government had...